Trial Profile
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Oedema Secondary to Central Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms CRUISE
- Sponsors Genentech
- 01 Mar 2022 Results of post hoc analysis, identifing anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion, published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 15 Aug 2014 New trial record
- 06 May 2010